Can animal data translate to innovations necessary for a new era of patient-centred and individualised healthcare? Bias in preclinical animal research

BMC Medical Ethics

Susan Bridgwood Green¹ 

[1] SABRE Research UK, London NW3 4UJ, UK

关键词: Phase 1 trials;    Waste in research;    Reproducibility;    Translational;    Pre-clinical;    Patients;    Research volunteers;    Animal models;    Bias;    Systematic review;   

Others  :  1221383
DOI  :  10.1186/s12910-015-0043-7

 received in 2014-11-27, accepted in 2015-07-14,  发布年份 2015

【 摘 要 】

Background

The public and healthcare workers have a high expectation of animal research which they perceive as necessary to predict the safety and efficacy of drugs before testing in clinical trials. However, the expectation is not always realised and there is evidence that the research often fails to stand up to scientific scrutiny and its 'predictive value' is either weak or absent.

Discussion

Problems with the use of animals as models of humans arise from a variety of biases and systemic failures including: 1) bias and poor practice in research methodology and data analysis; 2) lack of transparency in scientific assessment and regulation of the research; 3) long-term denial of weaknesses in cross-species translation; 4) profit-driven motives overriding patient interests; 5) lack of accountability of expenditure on animal research; 6) reductionist-materialism in science which tends to dictate scientific inquiry and control the direction of funding in biomedical research.

Summary

Bias in animal research needs to be addressed before medical research and healthcare decision-making can be more evidence-based. Research funding may be misdirected on studying 'disease mechanisms' in animals that cannot be replicated outside tightly controlled laboratory conditions, and without sufficient critical evaluation animal research may divert attention away from avenues of research that hold promise for human health. The potential for harm to patients and trial volunteers from reliance on biased animal data ¹requires measures to improve its conduct, regulation and analysis. This article draws attention to a few of the many forms of bias in animal research that have come to light in the last decade and offers a strategy incorporating ten recommendations stated at the end of each section on bias. The proposals need development through open debate and subsequent rigorous implementation so that reviewers may determine the value of animal research to human health. The 10Rs + are protected by a Creative Commons Attribution 3.0 Unported License and therefore may be 'shared, remixed or built on, even commercially, so long as attributed by giving appropriate credit with a link to the license, and indicate if changes were made.’

【 授权许可】

   
2015 Green.

【 参考文献 】

• [1]Ioannidis JPA. Extrapolating from animals to humans. Sci Transl Med. 2012; 4:151.
• [2]Bracken MB. Why are so many epidemiology associations inflated or wrong? Does poorly conducted animal research suggest implausible hypotheses? Ann Epidemiol. 2009; 3:220-4.
• [3]Collins FS, Tabak LA. NIH plans to enhance reproducibility. Nature. 2014; 505:612-3.
• [4]Mobley A, Linder SK, Braeuer R, Ellis LM, Zwelling L. A survey on data reproducibility in cancer research provides insights into Our limited ability to translate findings from the laboratory to the clinic. PLoS One. 2013; 8: Article ID e63221
• [5]Horn J, de Haan RJ, Vermeulen M, Luiten PG, Limburg M. Nimodipine in animal model experiments of focal cerebral ischemia: a systematic review. Stroke. 2001; 32:2433-8.
• [6]Sena ES, van der Worp HB, Bath PM, Howells DW, Macleod MR. Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol. 2010; 8:1-8.
• [7]Hillaire-Buys D, Faillie JL, Montastruc JL. Pioglitazone and bladder cancer. Lancet. 2011; 378:1543-1544.
• [8]Cohen D. Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed? BMJ. 2013; 346:f3680.
• [9]Gene Therapy Trial and Errors Raise Scientific, Ethical and Oversight Questions. 2000.
• [10]Macleod MR, Michie S, Roberts I, Dirnagl U, Chalmers I, Ioannidis JP, Al-Shahi Salman R, Chan AW, Glasziou P. Biomedical research: increasing value, reducing waste. Lancet. 2014; 383:2-6.
• [11]Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. Challenges and Opportunities Report US Department of Health and Human Services. FDA, US; 2004.
• [12]Grant files. 2014.
• [13]Grant files. 2007.
• [14]Arrowsmith J. Trial watch: phase II failures: 2008–2010. Nat Rev Drug Discov. 2011; 10:328-9.
• [15]Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004; 8:711-5.
• [16]Glasziou P, Altman DG, Bossuyt P, Bossuyt P, Boutron I, Clarke M, Julious S, Michie S, Moher D, Wager E. Reducing waste from incomplete or unusable reports of biomedical research. Lancet. 2014; 18:267-76.
• [17]Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. Lancet. 2009; 374:86-9.
• [18]Glasziou P. The role of open access in reducing waste in medical research. PLoS Med. 2014; 11: Article ID e1001651
• [19]Evans I, Thornton H, Chalmers I. Testing treatments: better research for better healthcare. 2006.
• [20]James Lind Alliance. http://www. lindalliance.org/ webcite
• [21]Sloff M, de Vries R, Geutjes P, IntHout J, Ritskes-Hoitinga M, Oosterwijk E, Feitz W. Tissue engineering in animal models for urinary diversion: a systematic review. PLoS One. 2014; 9: Article ID e98734
• [22]Morgan M, Barry CA, Donovan JL, Sandall J, Wolfe CD, Boaz A. Implementing 'translational' biomedical research: convergence and divergence among clinical and basic scientists. Soc Sci Med. 2011; 73:945-52.
• [23]Geerts H. Of mice and Men: bridging the translational disconnect in CNS drug discovery. CNS Drugs. 2009; 23:915-926.
• [24]Department of Health and Human Services Funding opportunities. 2013.
• [25]Plenge RM, Scolnick EM, Altshuler D. Validating therapeutic targets through human genetics. Nat Rev Drug Discov. 2013; 8:581-94.
• [26]Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, Finnerty CC, López CM, Honari S, Moore EE, Minei JP, Cuschieri J, Bankey PE, Johnson JL, Sperry J, Nathens AB, Billiar TR, West MA, Jeschke MG, Klein MB, Gamelli RL, Gibran NS, Brownstein BH, Miller-Graziano C, Calvano SE, Mason PH et al.. Genomic responses in mouse models poorly mimic human inflammatory diseases. PNAS. 2013; 110:3507-12.
• [27]Bestor TH. Gene silencing as a threat to gene therapy. J Clin Invest. 2000; 105:409-411.
• [28]Pound P, Britten N, Morgan M, Yardley L, Pope C, Daker-White G, Campbell R. Resisting medicines: a synthesis of qualitative studies of medicine taking. Soc Sci Med. 2005; 61:133-55.
• [29]Cooney GM, Dwan K, Greig CA, Lawlor DA, Rimer J, Waugh FR, McMurdo M, Mead GE. Exercise for depression. Cochrane Database Syst Rev. 2013; 9: Article ID CD004366
• [30]Arrowsmith J. Trial watch: phase III and submission failures: 2007–2010. Nat Rev Drug Discov. 2011; 10:87.
• [31]Collins F. Of mice, men and medicine. http://directorsblog. nih.gov/of-mice-men-and-medicine/comment-page-1/#comment-4902 webcite
• [32]Mak IW, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res. 2014; 6:114-118.
• [33]Booth B. Academic bias and biotech failures. http://lifescivc. com/2011/03/academic-bias-biotech-failures/#0_undefined,0 webcite
• [34]Science Exchange. Reproducibility Initiative. http://validation. scienceexchange.com/#/partners webcite
• [35]Fugh-Berman A. How basic scientists help the pharmaceutical industry market drugs. PLoS Biol. 2013; 11: Article ID e1001716
• [36]Festing MF. Fifty years after Russell and Burch, toxicologists continue to ignore genetic variation in their test animals. Altern Lab Anim. 2009; 37:1-5.
• [37]Begley CG, Ellis LM. Drug development: Raise standards for preclinical cancer research. Nature. 2012 Mar 28;483(7391):531-3.
• [38]Kimmelman J, Anderson JA. Should preclinical studies be registered? Nature Biotech. 2012; 30:488-9.
• [39]Roberts I, Kwan I, Evans P, Haig S. Does animal experimentation inform human healthcare? Observations from a systematic review of international animal experiments on fluid resuscitation. BMJ. 2002; 324:474-6.
• [40]Booth A. 2nd International Symposium on Systematic Reviews in Laboratory Animal Science. Registration of experimental studies and systematic reviews, Edinburgh, UK; 2013.
• [41]Al-Shahi Salman R, Beller E, Kagan J, Hemminki E, Phillips RS, Savulescu J, Macleod M, Wisely J, Chalmers I. Increasing value and reducing waste in biomedical research regulation and management. Lancet. 2014; 383:176-85.
• [42]Baldwin AL, Schwartz GE, Hopp DH. Are investigators aware of environmental noise in animal facilities and that this noise may affect experimental data? J Am Assoc Lab Anim Sci. 2007; 46:45-51.
• [43]Niklas W, Homberger FR, Illgen-Wilke B, Jakobi K, Kraft V, Kunstyr I, Mahler M, Meyer H, Pohlmeyer-Esch G. Implications of infectious agents on results of animal experiments. Lab Anim. 1999; 33 Suppl 1:87.
• [44]Pritchett-Corning KR, Cosentino J, Clifford CB. Contemporary prevalence of infectious agents in laboratory mice and rats. Lab Anim. 2009; 43:165-73.
• [45]Kokolus KM, Capitano ML, Lee CT, Eng JW, Waight JD, Hylander BL, Sexton S, Hong CC, Gordon CJ, Abrams SI, Repasky EA. Baseline tumor growth and immune control in laboratory mice are significantly influenced by subthermoneutral housing temperature. Proc Natl Acad Sci. 2013; 110:20176-81.
• [46]Sorge RE, Martin LJ, Isbester KA, Sotocinal SG, Rosen S, Tuttle AH, Wieskopf JS, Acland EL, Dokova A, Kadoura B, Leger P, Mapplebeck JC, McPhail M, Delaney A, Wigerblad G, Schumann AP, Quinn T, Frasnelli J, Svensson CI, Sternberg WF, Mogil JS. Olfactory exposure to males, including men, causes stress and related analgesia in rodents. Nat Methods. 2014; 11:629-632.
• [47]Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research. PLoS Biol. 2010 Jun 29;8(6):e1000412.
• [48]Hooijmans C, de Vries R, Leenaars M, Ritskes-Hoitinga M. The Gold Standard Publication Checklist (GSPC) for improved design, reporting and scientific quality of animal studies GSPC versus ARRIVE guidelines. Lab Anim. 2011; 45:61.
• [49]Baker D, Lidster K, Sottomayor A, Amor S. Two years later: journals Are Not Yet enforcing the ARRIVE guidelines on reporting standards for Pre-clinical animal studies. PLoS Biol. 2014; 12: Article ID e1001756
• [50]Muhlhausler BS, Bloomfield FH, Gillman MW. Whole animal experiments should be more like human randomized controlled trials. PLoS Biol. 2013; 11: Article ID e1001481
• [51]ter Riet G, Korevaar DA, Leenaars M, Sterk PJ, Van Noorden CJ, Bouter LM, Lutter R, Elferink RP, Hooft L. Publication bias in laboratory animal research: a survey on magnitude, drivers, consequences and potential solutions. PLoS One. 2013; 7: Article ID e43404
• [52]Song F, Parekh S, Hooper L, Loke YK, Ryder J, Sutton AJ, Hing C, Kwok CS, Pang C, Harvey I. Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess. 2010; 14:1-193.
• [53]Tsilidis KK, Panagiotou OA, Sena ES, Aretouli E, Evangelou E, Howells DW, Al-Shahi Salman R, Macleod MR, Ioannidis JP. Evaluation of excess significance bias in animal studies of neurological diseasse. PLoS Biol. 2013; 11: Article ID e1001609
• [54]Leenaars M. Cochrane Canada: Systematic reviews of animal studies. 2014.
• [55]van Luijk J, Bakker B, Rovers MM, Ritskes-Hoitinga M, de Vries RB, Leenaars M. Systematic reviews of animal studies; missing link in translational research? PLoS One. 2014; 9: Article ID e89981
• [56]Sandercock P, Roberts I. Systematic reviews of animal experiments. Lancet. 2002; 360:586.
• [57]The ethics of research involving animals. Nuffield Council on Bioethics, London; 2005.
• [58]Perel P, Roberts I, Sena E, Wheble P, Briscoe C, Sandercock P, Macleod M, Mignini LE, Jayaram P, Khan KS. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ. 2007; 334:197.
• [59]Korevaar DA, Hooft L, ter Reit G. Systematic reviews and meta-analyses of preclinical studies: publication bias in laboratory animal experiments. Lab Anim. 2011; 45:225-30.
• [60]Sena E, van der Worp HB, Howells D, Macleod M. How can we improve the pre-clinical development of drugs for stroke? Trends Neurosci. 2007; 30:433-439.
• [61]User guide for micro, small and medium-sized enterprises. European Medicines Agency, London; 2013.
• [62]Gøtzsche PC. Human guinea pig asks for animal studies. BMJ. 2014; 30:349.
• [63]Rawlins MD. Opinion:Cutting the cost of drug development? Nat Rev Drug Discov. 2004; 4:360-4.
• [64]Bennani YL. Drug discovery in the next decade: innovation needed ASAP. Drug Discov Today. 2012; 16 Suppl:S:31-44.
• [65]Russell WM, Burch RL. The Principles of Humane Experimental Technique. Methuen & Co Ltd, London; 1959.
• [66]Raza A. What scientific idea is ready for retirement?: Mouse models. http://www. theguardian.com/science/2014/jan/12/what-scientific-idea-is-ready-for-retirement-edge-org?CMP=twt_fd webcite
• [67]Editors [Unknown]: Inspections are Essential. ATLA 2013, 41(Suppl PiLAS):2–4 [http://pilas.org.uk/lost-in-translation-the-need-for-better-tools/].
• [68]House of Lords Select Committee on Animals in Scientific Procedures. Minutes of Evidence. http://www. publications.parliament.uk/pa/ld200102/ldselect/ldanimal/999/2051408.htm webcite
• [69]Guidance on the operation of the Animals (Scientific Procedures). 1986.
• [70]Peers IS, South MC, Ceuppens PR, Bright JD, Pilling E. Can you trust your animal study data? Nat Rev Drug Discov. 2014; 13:560.
• [71]Schuppli CA, Fraser D. Factors influencing the effectiveness of research ethics committees. J Med Ethics. 2007; 33:294-301.
• [72]Park IU, Peacey MW, Munafò MR. Modelling the effects of subjective and objective decision making in scientific peer review. Nature. 2014; 506:93-6.
• [73]Varga OE, Hansen AK, Sandøe P, Olsson IA. Improving transparency and ethical accountability in animal studies: three ways to link ethical approvals to publications. EMBO Rep. 2010; 11:500-3.
• [74]Rice MJ. The institutional review board is an impediment to human research: the result is more animal-based research. Philos Ethics Humanit Med. 2011; 6:12. BioMed Central Full Text
• [75]Abraham J, Ballinger R. Science, politics and health in the brave new world of pharmaceutical carcinogenic risk assessment: Technical progress or cycle of regulatory capture? Soc Sci Med. 2012; 75:1433-1440.
• [76]Calabrese EJ. Principles of Animal Extrapolation. Wiley, New York; 1983.
• [77]van Meer PJ, Kooijman M, Gispen-de Wied CC, Moors EH, Schellekens H. The ability of animal studies to detect serious post marketing adverse events is limited. Regul Toxicol Pharmacol. 2012; 64:345-9.
• [78]Varga OE, Hansen AK, Sandøe P, Olsson IA. Validating animal models for preclinical research: a scientific and ethical discussion. Altern Lab Anim. 2010; 38:245-8.
• [79]Wittevrongel C. The Three Rs - Do We Need a New Principle? Altern Lab Anim. 2013; 41:56-57.
• [80]Bailey J, Thew M, Balls M. An analysis of the use of dogs in predicting human toxicology and drug safety. Altern Lab Anim. 2013; 41:335-50.
• [81]Wendler A, Wehling M. Translatability scoring in drug development: eight case studies. J Transl Med. 2012; 10:39. BioMed Central Full Text
• [82]Corpet DE, Pierre F. How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men. Eur J Cancer. 2005; 41:1911-22.
• [83]Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T, Liu Y, Tupper T, Ouyang J, Li J, Gao P, Woo MS, Xu C, Yanagita M, Altabef A, Wang S, Lee C, Nakada Y, Peña CG, Sun Y, Franchetti Y, Yao C, Saur A, Cameron MD, Nishino M, Hayes DN, Wilkerson MD, Roberts PJ, Lee CB, Bardeesy N et al.. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature. 2012; 483:613-7.
• [84]Krauth D, Woodruff TJ, Bero L. Instruments for assessing risk of bias and other methodological criteria of published animal studies: a systematic review. Environ Health Perspect. 2013; 121:985-92.
• [85]Barnard DL. Animal models for the study of influenza pathogenesis and therapy. Antiviral Res. 2009; 82:A110-22.
• [86]Smee DF, Barnard DL. Methods for evaluation of antiviral efficacy against inflenza virus infections in animal models. Methods Mol Biol. 2013; 1030:407-25.
• [87]Improving the utility and translation of animal models for nervous system disorders: workshop summary. The National Academies Press, Washington DC; 2013.
• [88]Vesterinen HM, Currie GL, Carter S, Mee S, Watzlawick R, Egan KJ, Macleod MR, Sena ES. Meta-analysis of data from animal studies: a practical guide. J Neurosci Methods. 2013; 221C:92-102.
• [89]Nelson TJ: Science Notes: Why do so many new drugs fail in clinical testing? http://www. randombio.com/drug-failures.html webcite
• [90]Hartung T. Look back in anger - what clinical studies tell Us about preclinical work. ALTEX. 2013; 30:275-91.
• [91]Howick J, Glasziou P, Aronson KJ. Problems with using mechanisms to solve the problem of extrapolations. Theor Med Bioeth. 2013; 34:275-291.
• [92]JAXmice®. Find JAX Mice (Beta Release 1.0 search engine) [https://jaxmicesearch.jax.org/search#/]
• [93]The Jackson Laboratory. Humanized NSG mice.[http://jaxservices.jax.org/invivo/humanized-nsg.html].
• [94]Matthews RA. Medical progress depends on animal models - doesn't it? J R Soc Med. 2008; 101:95-8.
• [95]Peters JL, Sutton AJ, Jones DR, Rushton L, Abrams KR. A systematic review of systematic reviews and meta-analyses of animal experiments with guidelines for reporting. J Environ Sci Health B. 2006; 41:1245-58.
• [96]van Meer PKJ. The scientific value of non clinical animal studies in drug development. PhD thesis, Utrecht University; 2013.
• [97]The Jackson Laboratory. Stock number: 017914. http://jaxmice. jax.org/strain/017914.html webcite
• [98]Taconic. http://www. taconic.com/ webcite
• [99]The Jackson Laboratory. Find and order JAX® Mice. http://jaxmice. jax.org/findmice/ webcite
• [100]Labex of MA. Online catalogue. http://www. labexofma.com/results.php?CategoryID=0&ManufacturerID=0&Keyword=&ProductID=&Submit=Submit webcite
• [101]Grant J, Green L, Mason B. From Bedside to Bench: Comroe and Dripps Revisted. HERG Research Report No.30. Brunel University, London; 2003.
• [102]Comroe JH, Dripps RD. Scientific basis for the support of biomedical science. Science. 1976; 192:105-11.
• [103]Wooding S, Hanney S, Buxton M, Grant J. The returns from arthritis research. Vol. 1: Approach, analysis and recommendations. http://www. rand.org/pubs/monographs/MG251.html webcite
• [104]Wooding H, Hanney S, Pollitt A, Buxton M, Grant J. Project Retrosight: understanding the returns from cardiovascular and stroke research. http://www. rand.org/pubs/monographs/MG1079.html webcite
• [105]Wooding S, Pollitt A, Castle-Clarke S, Cochrane G, Diepeveen S, Guthrie S, Horvitz-Lennon M, Larivière V, Morgan Jones M, Ní Chonaill S, O’Brien C, Olmsted S, Schultz D, Winpenny E, Pincus H, Grant J. Mental Health Retrosight: Understanding the returns from research - lessons from schizophrenia (policy report). http://www. rand.org/pubs/research_reports/RR325.html webcite
• [106]Hartung T. Toxicology for the twenty-first century. Nature. 2009; 460:208-12.
• [107]DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003; 22:151-85.
• [108]Knox SS. From 'omics' to complex disease: a systems biology approach to gene-environment interactions in cancer. Cancer Cell Int. 2010; 26(10):11. BioMed Central Full Text
• [109]Kessler R, Glasgow RE. A proposal to speed translation of healthcare research into practice: dramatic change is needed. Am J Prev Med. 2011; 40:637-44.
• [110]Geerts H, Spiros A, Roberts P, Carr R. Quantitative systems pharmacology as an extension of PK/PDmodeling in CNS research and development. J Pharmacokinet Pharmacodyn. 2013; 40:257-65.
• [111]Geerts H, Roberts P, Spiros A, Carr R. Strategy for developing new treatment paradigms for neuropsychiatric and neurocognitive symptoms in Alzheimer’s disease. Front Pharmacol. 2013; 4:47.
• [112]Wyss Institute. Harvard's Wyss Institute and AstraZeneca announce collaboration on Organs-on-Chips for drug safety testing. http://wyss. harvard.edu/viewpressrelease/127/ webcite
• [113]Engber D. The Mouse Trap. http://www. slate.com/articles/health_and_science/the_mouse_trap/2011/11/the_mouse_trap.html webcite
• [114]Sumner P, Vivian-Griffiths S, Boivin J, Williams A, Venetis CA et al.. The association between exaggeration in health related science news and academic press releases: retrospective observational study. BMJ. 2014; 349:g7015.
• [115]PhRMA. Drug Discovery and Development. http://www. forbes.com/sites/matthewherper/2012/02/10/the-truly-staggering-cost-of-inventing-new-drugs/ webcite
• [116]Measuring the return from pharmaceutical innovation: weathering the storm: Annual Report. Deloitte LLP, London; 2013.
• [117]Gøtzsche P. Deadly Medicines and Organised Crime: How Big Pharma has Corrupted Healthcare. Radcliffe Publishing, London; 2013.
• [118]Baker M. Through the eyes of a mouse. Nature. 2013; 502:156-158.
• [119]Wang MM, Xi G, Keep RF. Should the STAIR criteria be modified for preconditioning studies? Transl Stroke Res. 2013; 4:3-14.
• [120]Greenhalgh T, Howick J, Maskrey N. Evidence based medicine: a movement in crisis? BMJ. 2014; 348:g3725.
• [121]The Right to Research Coalition. Right to Research campaign. http://www. righttoresearch.org webcite
• [122]The Open Access Button:. https://www. openaccessbutton.org/ webcite
• [123]Festing MF. We Are Not born knowing How to design and analyse scientific experiments. ATLA. 2013; 41:1-3.